Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma - Takeaways - MDSpire

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

Share

  • 1

    A new clinical trial is being conducted to explore adding low-dose oral chemotherapy to immunotherapy for melanoma patients.

  • 2

    The trial is led by Warren Chow, MD, and sponsored by the UC Irvine Anti-Cancer Challenge.

  • 3

    The study focuses on patients who have progressed after first-line immunotherapy treatment.

  • 4

    Cyclophosphamide is the chemotherapy drug being tested in a continuous regimen to combat resistance.

  • 5

    Results from the trial may provide insights by ASCO 2027 to enhance treatment options for melanoma patients.

Original Source(s)

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

  • June 24, 2026

Related Content

SNAP Participation and Cancer Screening for Adults With Food Insecurity

Human Papillomavirus–Related Cancer in People With HIV and Solid Organ Transplant Recipients

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making